Target Name: RTL9
NCBI ID: G57529
Review Report on RTL9 Target / Biomarker Content of Review Report on RTL9 Target / Biomarker
RTL9
Other Name(s): mammalian retrotransposon-derived 9 | retrotransposon gag domain containing 1 | RTL9 variant 2 | Retrotransposon Gag like 9, transcript variant 2 | MAR9 | RGAG1 | SIRH10 | Tumor antigen BJ-HCC-23 | Tumor antigen BJHCC23 | tumor antigen BJHCC23 | KIAA1318 | Retrotransposon Gag-like protein 9 | retrotransposon Gag like 9 | Sushi-Ichi retrotransposon homolog 10 | RTL9_HUMAN | tumor antigen BJ-HCC-23 | MART9 | retrotransposon gag domain-containing protein 1

Identifying RTL9 as A Potential Drug Target and Biomarker

Retrotransposon-derived 9 (RTL9) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in mammalian systems. RTL9 is a transcribed DNA fragment that is derived from a retrotransposon, which is a type of DNA transposition event that allows for the insertion of foreign DNA sequences into a native DNA molecule. In mammalian systems, retrotransposons have been identified as potential drug targets due to their ability to be targeted by small molecules and have been shown to be involved in a variety of cellular processes , including cell growth, differentiation, and inflammation.

One of the unique features of RTL9 is its potential to be a drug target due to its high stability and expression levels. RTL9 is a non-coding RNA molecule that is expressed in a variety of mammalian tissues and has been shown to have a long half-life, which is an important characteristic for a drug target. This stability allows for RTL9 to be effectively targeted by small molecules, which are often used to inhibit the activity of RTL9.

In addition to its stability, RTL9 has also been shown to have a complex structure that makes it an attractive target for small molecules. The 5' end of RTL9 contains a spliced 鈥嬧?婻NA molecule that is able to interact with the 3' end of the RTL9 fragment. This interaction allows for the potential for small molecules to bind to the 5' end of RTL9 and inhibit its activity.

Another feature of RTL9 that makes it an attractive drug target is its role in the development and progression of cancer. RTL9 has been shown to be involved in a variety of cellular processes that are associated with cancer development, including cell growth, apoptosis, and angiogenesis . This involvement makes RTL9 an attractive target for small molecules that are able to inhibit these processes.

In addition to its potential as a drug target, RTL9 has also been shown to be a potential biomarker for cancer. By measuring the levels of RTL9 in cancer cells, researchers have been able to monitor the effectiveness of different treatments and determine whether an treatment is having the desired effect. This ability to be used as a biomarker makes RTL9 an attractive target for cancer treatments.

In conclusion, RTL9 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in mammalian systems. Its stability, complex structure, and involvement in cellular processes that are associated with cancer development make it an attractive target for small molecules. Further research is needed to determine the full potential of RTL9 as a drug target and biomarker.

Protein Name: Retrotransposon Gag Like 9

The "RTL9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RTL9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RTN1 | RTN2 | RTN3 | RTN4 | RTN4IP1 | RTN4R | RTN4RL1 | RTN4RL2 | RTP1 | RTP2 | RTP3 | RTP4 | RTP5 | RTRAF | RTTN | RUBCN | RUBCNL | RUFY1 | RUFY2 | RUFY3 | RUFY4 | RUNDC1 | RUNDC3A | RUNDC3A-AS1 | RUNDC3B | RUNX1 | RUNX1-IT1 | RUNX1T1 | RUNX2 | RUNX2-AS1 | RUNX3 | RUNX3-AS1 | RUSC1 | RUSC1-AS1 | RUSC2 | RUSF1 | RUVBL1 | RUVBL1-AS1 | RUVBL2 | RWDD1 | RWDD2A | RWDD2B | RWDD3 | RWDD3-DT | RWDD4 | RXFP1 | RXFP2 | RXFP3 | RXFP4 | RXRA | RXRB | RXRG | RXYLT1 | Ryanodine receptor | RYBP | RYK | RYR1 | RYR2 | RYR3 | RZZ complex | S100 Calcium Binding Protein | S100A1 | S100A10 | S100A11 | S100A11P1 | S100A12 | S100A13 | S100A14 | S100A16 | S100A2 | S100A3 | S100A4 | S100A5 | S100A6 | S100A7 | S100A7A | S100A7L2 | S100A7P1 | S100A8 | S100A9 | S100B | S100G | S100P | S100PBP | S100Z | S1PR1 | S1PR1-DT | S1PR2 | S1PR3 | S1PR4 | S1PR5 | SAA1 | SAA2 | SAA2-SAA4 | SAA3P | SAA4 | SAAL1 | SAC3D1 | SACM1L | SACS